2 unter bewertete papiere!!Nano+Bio!!
04.03.04 00:05
#1
azel
2 unter bewertete papiere!!Nano+Bio!!
habe 2 aktien die bestimmt was bringen!bin selber noch nicht drin! 1.biopure corp. wkn 924810 (aus dem letzten biotech report)Markt.60 mio. $ umsatz 04 4,8 milo.$ umsatz (voraussichtlich 05 , 62 milo $)bio unternehmen! Dann ein Nanotech unternehmen aus USA Xtrana (kürzel:xtrn.ob)marktk.1,4 milo € kurs ca 0,11€ !!!lohnt sich da was!!
04.03.04 00:16
#2
azel
hier paar news zu wkn 924810
Cauley Geller Announces Biopure Corporation Investors Have Until March 1 to File Lead Plaintiff Motion -- BPUR
Tuesday February 24, 3:46 pm ET
NEW YORK, Feb. 24, 2004 (PRIMEZONE) -- The deadline for purchasers of Biopure Corporation (``Biopure'' or the ``Company'') (NasdaqNM:BPUR - News) publicly traded securities to move for lead plaintiff in a securities fraud class action recently brought against the Company is rapidly approaching. If you purchased Biopure publicly traded securities between March 17, 2003 and December 24, 2003, inclusive (the ``Class Period'') and you wish to be a lead plaintiff in the case, you must move to serve as lead plaintiff by filing a motion in the United States District Court for the District of Massachusetts by March 1, 2004. A copy of the complaint filed in this action is available from the Court, or can be viewed on the firm's website at http://www.cauleygeller.com/show_case.asp?ccode=212&pcode=10&pp=4.
ADVERTISEMENT
The complaint, filed by a client of Cauley Geller Bowman & Rudman, LLP, charges Biopure, Thomas A. Moore, Carl W. Rausch and Ronald F. Richards with violations of Sections 10(b)and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder. The Complaint alleges that, throughout the Class Period, defendants issued numerous positive statements concerning the progress of its application to the U.S. Food and Drug Administration (``FDA'') seeking regulatory approval to market Hemopure in the United States for patients undergoing orthopedic surgery. In truth and in fact, however, by the beginning of the Class Period, the FDA had informed defendants of flaws in the Hemopure application, citing ``safety concerns'' arising from adverse clinical data submitted as part of the Company's application, making FDA approval highly unlikely. Prior to the disclosure of these adverse facts, defendants conducted at least two offerings of Biopure common stock generating millions of dollars in proceeds and certain high-level Biopure insiders sold hundreds of thousands of Biopure common shares to the unsuspecting investing public at artificially inflated prices.
Then, on December 24, 2003, under the threat of civil litigation by the SEC, defendants stunned the market by announcing that, in fact, the FDA had halted further clinical trials of Hemopure due to safety concerns. Defendants also disclosed that the commercial release of Hemopure in the United States would be delayed beyond mid-2004. Market reaction to defendants' belated disclosures was swift and severe. On December 26, 2003, Biopure common shares lost over 16% of their value to close at $2.43 per share, representing a decline of more than 239% from a Class Period high of $8.25 per share, reached on or about August 21, 2003.
If you bought Biopure publicly traded securities between March 17, 2003 and December 24, 2003, inclusive, and you wish to serve as lead plaintiff, you must move the Court no later than March 1, 2004. If you are a member of this class, you can join this class action online at http://www.cauleygeller.com/template8.asp?pcode=6&pp=1. Any member of the purported class may move the Court to serve as lead plaintiff through Cauley Geller or other counsel of their choice, or may choose to do nothing and remain an absent class member.
Cauley Geller is a national law firm that represents investors and consumers in class action and corporate governance litigation. It is one of the country's premier firms in the area of securities fraud, with in house finance and forensic accounting specialists and extensive trial experience. Since its founding, Cauley Geller has recovered in excess of two billion dollars on behalf of aggrieved shareholders. The firm maintains offices in Boca Raton, Little Rock and New York.
If you have any questions about how you may be able to recover for your losses, or if you would like to consider serving as one of the lead plaintiffs in this lawsuit, you are encouraged to call or e mail the Firm or visit the Firm's website at http://www.cauleygeller.com. zuzeit absolut tief . das hoch ist bei ca. 9$,jetzt bei 1,6$
Tuesday February 24, 3:46 pm ET
NEW YORK, Feb. 24, 2004 (PRIMEZONE) -- The deadline for purchasers of Biopure Corporation (``Biopure'' or the ``Company'') (NasdaqNM:BPUR - News) publicly traded securities to move for lead plaintiff in a securities fraud class action recently brought against the Company is rapidly approaching. If you purchased Biopure publicly traded securities between March 17, 2003 and December 24, 2003, inclusive (the ``Class Period'') and you wish to be a lead plaintiff in the case, you must move to serve as lead plaintiff by filing a motion in the United States District Court for the District of Massachusetts by March 1, 2004. A copy of the complaint filed in this action is available from the Court, or can be viewed on the firm's website at http://www.cauleygeller.com/show_case.asp?ccode=212&pcode=10&pp=4.
ADVERTISEMENT
The complaint, filed by a client of Cauley Geller Bowman & Rudman, LLP, charges Biopure, Thomas A. Moore, Carl W. Rausch and Ronald F. Richards with violations of Sections 10(b)and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder. The Complaint alleges that, throughout the Class Period, defendants issued numerous positive statements concerning the progress of its application to the U.S. Food and Drug Administration (``FDA'') seeking regulatory approval to market Hemopure in the United States for patients undergoing orthopedic surgery. In truth and in fact, however, by the beginning of the Class Period, the FDA had informed defendants of flaws in the Hemopure application, citing ``safety concerns'' arising from adverse clinical data submitted as part of the Company's application, making FDA approval highly unlikely. Prior to the disclosure of these adverse facts, defendants conducted at least two offerings of Biopure common stock generating millions of dollars in proceeds and certain high-level Biopure insiders sold hundreds of thousands of Biopure common shares to the unsuspecting investing public at artificially inflated prices.
Then, on December 24, 2003, under the threat of civil litigation by the SEC, defendants stunned the market by announcing that, in fact, the FDA had halted further clinical trials of Hemopure due to safety concerns. Defendants also disclosed that the commercial release of Hemopure in the United States would be delayed beyond mid-2004. Market reaction to defendants' belated disclosures was swift and severe. On December 26, 2003, Biopure common shares lost over 16% of their value to close at $2.43 per share, representing a decline of more than 239% from a Class Period high of $8.25 per share, reached on or about August 21, 2003.
If you bought Biopure publicly traded securities between March 17, 2003 and December 24, 2003, inclusive, and you wish to serve as lead plaintiff, you must move the Court no later than March 1, 2004. If you are a member of this class, you can join this class action online at http://www.cauleygeller.com/template8.asp?pcode=6&pp=1. Any member of the purported class may move the Court to serve as lead plaintiff through Cauley Geller or other counsel of their choice, or may choose to do nothing and remain an absent class member.
Cauley Geller is a national law firm that represents investors and consumers in class action and corporate governance litigation. It is one of the country's premier firms in the area of securities fraud, with in house finance and forensic accounting specialists and extensive trial experience. Since its founding, Cauley Geller has recovered in excess of two billion dollars on behalf of aggrieved shareholders. The firm maintains offices in Boca Raton, Little Rock and New York.
If you have any questions about how you may be able to recover for your losses, or if you would like to consider serving as one of the lead plaintiffs in this lawsuit, you are encouraged to call or e mail the Firm or visit the Firm's website at http://www.cauleygeller.com. zuzeit absolut tief . das hoch ist bei ca. 9$,jetzt bei 1,6$
04.03.04 00:20
#3
azel
news zu xtrana wkn 889427
BROOMFIELD, Colo.--(BUSINESS WIRE)--Jan. 29, 2004--Xtrana, Inc. (OTCBB:XTRN - News) announced today that it has entered into a definitive agreement to sell all of its intellectual property for $4,000,000.
These assets include all of Xtrana's intellectual property assets, excluding Xtrana's trademarks and trade names.
Completion of the sale is subject to a number of closing conditions, including the approval of a majority of Xtrana's stockholders to be solicited at a Special Meeting of Stockholders scheduled for March this year.
Tim Dahltorp, Xtrana's CEO, commented: "After an extensive review of alternatives available to the Company, including raising additional capital, licensing, co-development partnerships, and the sale of part or all of the Company's assets, the Board of Directors concluded the sale of the Company's intellectual property provided the best economic benefit to the Company and its shareholders." Mr. Dahltorp continued: "The proceeds from the transaction could attract interest from other operating businesses that might benefit from access to those funds, as well as our tax loss carry forward and our status as a public company with a clean reporting history. Such interest could result in us merging or otherwise joining together with an existing business that could create long-term stockholder value. After closing the transaction, it is the intention of the Board of Directors to spend a reasonable period of time exploring opportunities to find other transactions that it believes would provide long-term stockholder value, and if no such transactions are identified, to propose that the stockholders approve a liquidation with the proceeds being distributed to shareholders. In either event, the Board of Directors does not anticipate taking any action without further stockholder approval."
Xtrana, Inc. develops, manufactures and markets novel nucleic acid extraction kits and detection systems for use in molecular diagnostics, drug discovery, forensics, research, clinical and life sciences markets. To learn more about Xtrana, visit the Company's web site at www.xtrana.com.
This press release contains forward-looking statements (identified by the words "estimate," "anticipate," "expect," "believe," and similar expressions), which are based upon management's current expectations and speak only as of the date made. These forward-looking statements are subject to risks, uncertainties and factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements and include, but are not limited to, competitors' pricing strategies and technological innovations, changes in health care and government regulations, litigation claims, foreign currency fluctuation, product acceptance, as well as other factors discussed in the Company's last report
These assets include all of Xtrana's intellectual property assets, excluding Xtrana's trademarks and trade names.
Completion of the sale is subject to a number of closing conditions, including the approval of a majority of Xtrana's stockholders to be solicited at a Special Meeting of Stockholders scheduled for March this year.
Tim Dahltorp, Xtrana's CEO, commented: "After an extensive review of alternatives available to the Company, including raising additional capital, licensing, co-development partnerships, and the sale of part or all of the Company's assets, the Board of Directors concluded the sale of the Company's intellectual property provided the best economic benefit to the Company and its shareholders." Mr. Dahltorp continued: "The proceeds from the transaction could attract interest from other operating businesses that might benefit from access to those funds, as well as our tax loss carry forward and our status as a public company with a clean reporting history. Such interest could result in us merging or otherwise joining together with an existing business that could create long-term stockholder value. After closing the transaction, it is the intention of the Board of Directors to spend a reasonable period of time exploring opportunities to find other transactions that it believes would provide long-term stockholder value, and if no such transactions are identified, to propose that the stockholders approve a liquidation with the proceeds being distributed to shareholders. In either event, the Board of Directors does not anticipate taking any action without further stockholder approval."
Xtrana, Inc. develops, manufactures and markets novel nucleic acid extraction kits and detection systems for use in molecular diagnostics, drug discovery, forensics, research, clinical and life sciences markets. To learn more about Xtrana, visit the Company's web site at www.xtrana.com.
This press release contains forward-looking statements (identified by the words "estimate," "anticipate," "expect," "believe," and similar expressions), which are based upon management's current expectations and speak only as of the date made. These forward-looking statements are subject to risks, uncertainties and factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements and include, but are not limited to, competitors' pricing strategies and technological innovations, changes in health care and government regulations, litigation claims, foreign currency fluctuation, product acceptance, as well as other factors discussed in the Company's last report
01.05.07 15:21
#5
nicday59
Biopure vor dem Aufbruch
laut Berichten der FDA und Analysen, steht Biopure vor dem Aufbruch. man rechnet sogar damit, dass ende Mai anfang Juni eine gute nachricht der FDA das Papier endlich flügel verleiht.
daher die Aktie mit aktuellem wert unter 0,60 US$ ist die beste chance zum Einsteigen.
02.05.07 17:03
#6
nicday59
Aufbruch und Ausbruch
ich hattees ja gestern allen mitgeteilt! na ja, wer liest der gewinnt!